Verition Fund Management
URGN icon

Verition Fund Management’s UroGen Pharma URGN Stock Holding History

Verition Fund Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-89,028
Closed -$1.78M – 3969
2025
Q3 		$1.78M Buy
+89,028
New +$1.6M 0.01% 2079
2025
Q1 		– Sell
-28,672
Closed -$305K – 3738
2024
Q4 		$305K Buy
28,672
+15,418
+116% +$185K ﹤0.01% 2773
2024
Q3 		$168K Buy
+13,254
New +$197K ﹤0.01% 2921
2023
Q4 		– Sell
-17,017
Closed -$238K – 2697
2023
Q3 		$238K Buy
+17,017
New +$273K ﹤0.01% 1875

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Verition Fund Management's URGN Position: Q4 2025 in Review

Verition Fund Management sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 89,028 shares — an estimated $1.78M sold.

Verition Fund Management first reported a position in URGN in Q3 2023 and held it in 4 quarters. The position peaked at $1.78M in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Verition Fund Management reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 89,028 UroGen Pharma shares in Q4 2025, an estimated $1.78M.
  • Verition Fund Management first reported a position in UroGen Pharma in Q3 2023 and held it in 4 quarters.
  • Verition Fund Management's UroGen Pharma position peaked at $1.78M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.